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It  has been  recently reported (1-3)  that  the complement receptor for C3b 
(CR1) has a unique role in the degradation of C3b bound to the cell membrane 
or to  immune complexes (*C3b).  CR1  can  be  more effective (4)  than  serum 
factor H  in promoting the I-mediated transformation of *C3b into the bemolyt- 
ically inactive intermediate *iC3b (5). Moreover, under physiological conditions, 
CR1, but not H, serves as a cofactor for the further cleavage of *iC3b into C3c 
and  *C3dg,  the  ligand for the  C3d  receptor (CR2)  (1-3).  These findings,  in 
conjunction with other evidence (6-10), have been interpreted as meaning that 
the processing of *C3b-containing antigen-antibody complexes in vivo occurs on 
the surface of red cells (which bear most of the CR 1 in human peripheral blood), 
and as indicative that  the CR1  deficiencies observed in patients with systemic 
lupus erythematosus and rheumatoid arthritis (11-15) might be involved in the 
pathogenesis of these immune complex diseases. 
When the complement cascade is triggered by the classic pathway, both *C3b 
and *C4b bind covalently to the activating substrate and participate in formation 
of the enzymes C3-convertase (C4b,2a) and C5-convertase (C4b,2a,3b), which in 
turn augment the cascade reaction (reviewed in 16). Since *C4b, which regulates 
the activity of both enzymes, is also a  ligand for CR1  (17,  18),  and CR1  can 
inhibit both enzymes (19), we study here the effects of the interaction between 
red cell intermediates bearing C3 and C5 convertases and CR1  in the presence 
of serum factor I.  We present evidence not only that CR1  may be a  principal 
cofactor responsible for the physiological degradation of *C4b, but also that the 
inactivation of *C4b can be greatly enhanced when sufficient *C3b is deposited 
in its vicinity. Likewise, the inactivation of *C3b is enhanced by adjacent *C4b. 
Materials and Methods 
Buffers, Reagents, and  Proteins.  Isotonic  veronal-buffered saline  (DGVB++)  ~ used  in 
most studies contained 2.5 mM veronal, pH 7.4, 73 mM NaC1, 2.5% dextrose, 0.15 mM 
CaCI2,  1 mM MgCl~, and 0.1%  gelatin.  Isotonic  veronal  buffer (GVB  ÷+) used in some 
This work was supported by grants from the Systemic Lupus Erythematosus Societies of Illnois and 
New York, the Arthritis Foundation, and the Kroc Foundation, and by grant AI-08499 from the 
National Institutes of Health. 
Abbreviations  used in  this paper:  DGVB  +÷, isotonic veronal-buffered saline containing 2.5 mM 
veronal, pH 7.3, 73 mM NaCI, 2.5% dextrose, 0.15 mM CaCI~, 1 mM MgCI~, and 0.1% gelatin; E  hu, 
human erythrocytes; GVB  ++, isotonic veronal buffer prepared as DGVB  ÷+ except with 146 mM NaCI 
instead of 73  mM NaCl and dextrose; KSCN, potassium thiocyanate; NP-40, Nonidet P-40; PBS, 
phosphate-buffered saline; SFU, site-forming unit; SDS-PAGE, sodium dodecyl sulfate-polyacrylam- 
ide gel electrophoresis. 
J. ExP. MEo. © The Rockefeller University Press • 0022-1007/84/06/1669/17 $1.00  1669 
Volume 159  June 1984  1669-1685 1670  CONTROL OF  C4b-C3b BY  COMPLEMENT  RECEPTOR  CR1 
experiments contained 146 mM NaCI instead of 73 mM NaCI and 2.5% dextrose. Metal- 
chelating veronal buffer (GVB-EDTA), used in hemolytic assays and for washing cells, 
contained 10 mM EDTA and lacked CaCI~ and MgCl~. 
C4 and C3 were purified from DEAE-Sephacel fractions of pooled human plasma by 
polyethylene glycol precipitation followed by DEAE-Sephacel rechromatography or Seph- 
adex G-200 gel filtration, respectively (20). C4 contained no C3 or C5 hemolytic activity, 
and  its  specific  activity was  1.1  x  106  C4  site-forming  units  (SFU)  per  mg  protein 
immediately after purification. It was stored at 4°C  in sterile tubes containing 25 mM 
benzamidine. C 3 was depleted of residual C5 and H activities by adsorption with Sepharose 
anti-human C5 and anti-human H, respectively. The specific activity of C3 was 8 X 103 
SFU/mg. It was stored frozen in aliquots at -70°C. C2 (21) and C5 (20) were purified as 
described, and in some experiments C2 was  used in an oxidized form (°~YC2) (22).  C1 
(23), C6-9 (24), and C-EDTA were prepared from guinea pig serum. C4b was prepared 
by "spontaneous" conversion of C4 upon removal of benzamidine by dialysis. 
I  (25),  C4bp  (26),  H  (20),  and  CR1  (5,  19)  were purified as  described.  I  was  also 
obtained commercially (Cordis  Laboratories Inc.,  Miami,  FL).  C4bp  was  depleted of 
contaminating IgM and H by adsorption with Sepharose anti-IgM and anti-H, respectively. 
The final product consisted predominantly of the higher molecular weight form (26). H 
was  depleted  of contaminating  IgA  by  adsorption  with  Sepharose-anti-IgA.  For  the 
purification of CR1,  0.1%  Nonidet P-40  (NP-40) extracts of human  erythrocyte (E  h") 
stroma were chromatographed on Biorex-70 (Bio-Rad Laboratories, Richmond, CA) as 
described (5). After salt gradient elution, the fractions containing CR1 (as determined by 
their inhibitory activity on C5-convertase, C4b,2a,3b) were pooled, concentrated, and 
filtered through Sepharose-anti-CR1 prepared with two monoclonal antibodies (44D and 
57H) (12, 19). After washing, the bound CR1 was eluted with 3 M potassium thiocyanate 
(KSCN).  Excess KSCN  was removed by passage of the eluate through Sephadex G-25 
equilibrated in phosphate-buffered saline (PBS) containing 0.1% NP-40. The final product 
contained negligible impurities as assessed  by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions followed by silver staining (Bio- 
Rad Laboratories). 
E  h° were purified from acid/citrate/dextrose-treated venous blood samples from healthy 
volunteers. Cells  were washed five times with large volumes of GVB-EDTA and buffy 
coats aspirated to remove white blood cells.  The remaining E  hu were washed twice in 
DGVB  ÷+ and resuspended to appropriate concentration. 
SDS-PAGE.  SDS-PAGE was performed as described by Laemmli (27). Stacking gels of 
3% and running gels of 7.5% were used. Samples were reduced by the addition of 20% 
2-mercaptoethanol to the sample buffer. Molecular weights were estimated by comparison 
with a set of commercially available standards (Bethesda Research Laboratories, Rockville, 
MD). Gels were fixed and stained with methanol/acetic acid containing Coomassie Blue. 
Radioautographs were exposed at -70°C using X-Omat R film (XR-5; Eastman Kodak 
Co., Rochester, NY). 
Radiolabeling.  C4 and C3 were labeled with ~5I or ~lI using Iodogen (Pierce Chemical 
Co.,  Rockford,  IL) as  per  the  manufacturer's  instructions.  Unbound  12~I or  13~I was 
eliminated by gel filtration through Sephadex G-25 QS-2A Quick-Sep columns (Isolab, 
Inc., Akron, OH) followed by dialysis. 
Cellular Intermediates and Hemolytic Assays.  Sheep erythrocytes (E) were sensitized with 
rabbit anti-sheep hemolysin (A) (Gibco Laboratories, Grand Island, NY) and the resulting 
EA washed and adjusted to  1 ×  108 cells/ml in DGVB  +÷. An equal volume of C1  at a 
dilution sufficient to provide 300 SFU was added and the mixture incubated 15 rain at 
30°C. After washing, the intermediates (EAC1) were incubated for 20 rain at 30°C with 
an  equal volume of an appropriate dilution of C4  to yield cells  (EACI4) bearing the 
amounts of *C4b specified in the text or figure legends. EAC14, 1 ×  108/ml in DGVB  ++, 
were incubated for 5 min at 30°C with 300 SFU/ml of C2 (or °~YC2) and the intermediates 
(EAC142 or EAC14°~YC2) washed, readjusted to 1 ×  108/ml in DGVB  ++, and incubated 
with an equal volume of C3 at a dilution sufficient to yield cells (EAC 1423 or EAC 14°~Y23) 
bearing the specified amount of *C3b. C4b hemolytic sites were determined by sequential MEDOF  AND  NUSSENZWEIG  1671 
incubation of EAC14 with 300 SFU of °xYC2 for 5 min at 30°C and C-EDTA for  1 h at 
37°C. C3b hemolytic sites were determined by incubation of EAC1423 (or EAC14°xY23) 
with 300 SFU of C5 for 5 min at 30°C and C6-9 for 1 h at 37°C. The number of *C4b 
or *C3b molecules deposited on the erythrocytes was calculated from the percentage of 
uptake of samples containing l~sI-C4 or 12si-C3. 
C4c and C3c Release.  EAC14 bearing lZ~I-labeled *C4b were added in 25-#1 aliquots 
to reaction tubes containing 25-#1 volumes of I (or DGVB  ÷+ as control) and 50 #1 volumes 
of different dilutions of C4bp, CR1, or E  h" (or DGVB  +÷ as control). The final concentra- 
tions of the reactants are given in the text or figure legends. The tubes were incubated 
at either 37 or 30°C in a water bath and agitated periodically. The reaction was stopped 
by transfer of the tubes to an ice bath and addition of 900 #1 of ice-cold DGVB  ÷+. The 
cells were pelleted and 500 #! of supernatant was removed. The percentage of released 
C4 label was calculated from the counts present in the separated 500-#1 fraction and those 
remaining in the tube. Studies on the release of C4c or C3c from EAC1423 bearing ~25I- 
labeled *C3b or bearing both 12SI-labeled *C4b and 13q-labeled *C3b were performed as 
described above. 
Results 
Ability  of  CRI  to  Promote  I-mediated  Degradation  of  Substrate-bound  *C4b 
Previous studies (28) have indicated that the enhancing activity of C4bp on the 
I-mediated degradation of *C4b is observed only when the *C4b density reaches 
at least 3 ×  103 molecules per cell. To determine the effect of *C4b density on 
CR 1 activity, release of C4 label by I plus CR 1 was studied using EAC 14 prepared 
with different amounts of C4.  As shown in Fig.  1,  the cofactor activity of CR 1 
was not observed at low *C4b densities,  but increased  progressively when  the 
number of *C4b molecules surpassed 3 ×  l0 s per cell. 
The  effects of C4bp,  of purified  CR1,  and  of intact  E hu on  the  I-mediated 
breakdown of cell-bound *C4b into C4c and *C4d were then compared. In view 
of  the  results  shown  in  Fig.  1,  these  studies  were  performed  using  a  cell 
intermediate  EAC14  bearing  6  ×  l0 s  ~25I-*C4b  molecules per cell.  Cells (5  × 
107/ml in  DGVB  +÷) were mixed with  I  (16 gg/mi) plus CR1,  E hu, or C4bp, in 
increasing concentrations, or with each factor alone as control. After incubation 
at  37°C  for  60  min,  the  reactions  were  stopped  and  the  percentage  of C4 
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FIGURE  1.  Effect of *C4b density on the release of C4 fragments from EAC14. EAC14 (5 
x  107/ml) bearing increasing  amounts (5 × 102; 1.4, 3.7, or 7.3 × l0  s or 1.6 × 104 molecules/ 
cell) of 1~5I-*C4b  were incubated at 37°C for 1 h with 16 #g/ml of I and 800 ng/ml of CR1. 
The percentage of release  of  I-C4  radiolabel  is shown  as a  function of the density  of 
125  deposited  I-  C4b on the cells. About 10% release was observed in the presence of I alone 
at all *C4b densities. CR1 enhanced the release of C4 fragments only at *C4b densities >3 × 
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radiolabel released into the supernatant was determined. CR1, E h", and C4bp all 
enhanced  I-mediated release of radiolabe'l in a dose-dependent fashion (Fig.  2). 
As little as 50 ng/ml of purified CR1 or 6.2 X  107 Eh"/ml (containing ~60 ng/ 
ml of CR1) caused significant enhancement.  In contrast, as much as 30 #g/ml of 
C4bp had substantially less effect. Minimal  release occurred in the presence of 
CR1, E  hu, or C4bp alone. 
To verify whether  the  release  observed in  the  presence  of CR1  or E hu was 
mediated  in  fact by CR1  rather  than  by some other factor, additional  studies 
were performed  in  which  a  pool of purified  monoclonal  anti-CR1  antibodies 
(44D,  31 D, 57F) was added to the reaction mixtures.  Parallel studies were also 
performed  in  which  E h"  were  replaced  by  erythrocytes  from  animal  species 
known not to mediate immune adherence of EAC1423. As also shown in Fig. 2, 
the CR1- or Eh"-mediated release of C4 label was strongly inhibited by monoclo- 
nal antibodies to CR 1. Minimal release was observed in the presence of as many 
as twofold higher numbers of erythrocytes from guinea pigs or sheep (not shown). 
Modulation by *C3b of I plus CRl-mediated *C4b Degradation.  In the presence 
of C3,  *C4b,2a-bearing  substrates  can  rapidly  fix  *C3b.  Since  CR1  binds  to 
*C3b in addition to *C4b, we next studied the effect of deposited *C3b on the 
degradation  of substrate-bound  *C4b  by  I  plus  CRI.  EAC14  (5  X  107/ml) 
prepared with radiolabeled 125I-C4 and bearing ~3 x  103 molecules of *C4b per 
cell were incubated with excess C2. Then increasing amounts (3-81  SFU/ml) of 
unlabeled  C3  (or  DGVB  ÷÷  as  control)  were  added.  The  number  of  *C3b 
molecules deposited at each C3 input was calculated from parallel  experiments 
in which EAC14 were prepared with unlabeled C4 and the cells incubated with 
125I-C3.  The resulting cells bearing 3 x  103 molecules of 125I-labeled  *C4b and 
from 0  to  5  X  104 molecules of *C3b were then incubated at 37°C for 60 min 
with I (16 #g/ml) and increasing concentrations of CR1  (100-800 ng/ml).  In a 
second set of tubes, cells were incubated with the same concentration  of I and 
increasing concentrations of C4bp in comparable blood proportions (2.5-20 #g/ 
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FIGURE 2.  Comparative activities of C4bp, CR l, and E h" in promoting the I-mediated release 
of C4  fragments.  EAC14 (5  ×  107/ml) bearing 6  x  l0  s  125I-*C4b  molecules.per cell were 
incubated at 37°C for 60 min with I (16 #g/ml) plus C4bp, purified CR1, or E"" membrane- 
associated CR1  in increasing concentrations, or alternatively with I, DGVB  +÷, C4bp, CR1, or 
E h" alone as controls. Release of C4 radiolabel is shown as a function of cofactor input in #g/ 
ml. About 10S-fold more C4bp than purified or membrane-associated CR1  was required for 
comparable enhancement of release and no significant release occurred in the absence of I. 
Addition of a pool of three monoclonal anti-CR1 antibodies (3 I D, 44D and 57F), each at 15 
#g/ml, strongly inhibited CR 1- and Eh"-mediated enhancement of release. MEDOF  AND  NUSSENZWEIG  1673 
ml). The percentages of C4 radiolabel released from the red cells are shown in 
Fig.  3. Clearly,  *C3b fixation enhanced the I  plus CRl-mediated  C4 release in 
a dose-dependent fashion. Maximum enhancement of CR 1 activity (5-10-fold in 
different  experiments)  was  obtained  with  cells  bearing  2  ×  104  molecules  of 
*C3b  at  a  *C3b/*C4b  molar  ratio  of-8:1.  In  contrast,  in  this  and  other 
experiments,  *C3b suppressed the I  plus C4bp-mediated release of C4 radio|a- 
bel. Maximum suppression of approximately two- to fourfold was observed with 
cells bearing  5  ×  10  4  molecules of *C3b at a  *C3b/*C4b  molar ratio of 17:1. 
The release of C4 label by I alone was also inhibited by *C3b. 
The *C3b-mediated enhancement of the activity of CR 1 on *C4b degradation 
had two interesting and perhaps physiologically significant consequences.  First, 
this enhancement was also observed when *C4b densities were low. In Fig. 4, we 
show the  effect of I plus CR1  on  EAC1423  bearing only  1  ×  103  molecules of 
*C4b  but  increasing  numbers  of  *C3b  per  cell.  Clearly  *C3b  promoted  C4 
release from the EAC1423  cells and the effect was proportional to the amount 
of *C3b fixed. This result should be contrasted with those of Fig.  1 and of Fujita 
and Tamura (28) showing that CR1  and C4bp only enhance the activity of I on 
EAC14 if the density of *C4b is >3 ×  l0 s molecules per cell. 
Second,  we found that after *C3b fixation,  CR1  was active on  *C4b even in 
the presence of C2, which,  in previous studies (19), has been shown to competi- 
tively inhibit the binding of CR1 to *C4b. Our studies were performed as follows. 
EAC142 bearing 3  x  l0 s molecules of ~25I-*C4b per cell and saturating amounts 
of C2a were incubated with DGVB  +÷ or with C3 at a dilution sufficient to yield 
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FIGURE 3.  Effect of fixed *C3b on the I plus CRI- and I plus C4bp-mediated release of 
$  125  ,  substrate-bound  C4 fragment.  EAC14 (5 x  107/ml) bearing 3 x  10  molecules of  I- C4b 
per cell were incubated stepwise with 300 SFU of C2 and then either with DGVB  ++ or with 
increasing amounts of C3. The resulting cellular intermediates bearing a constant amount of 
*2sI-*C4b and the respective numbers of (unlabeled) *C3b molecules indicated in the figure 
were then incubated at 37°C for 60 min with 16 #g/ml I plus increasing concentrations  of 
CR1 or with the same concentration  of I plus comparable proportions  of the normal blood 
content of C4bp. The percentage of release of C4 radiolabel is shown as a function of CR1 or 
C4bp input. Release by I plus CRI increased as the amount of deposited *C3b was increased, 
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FIGURE 4.  Ability of CR1  to  augment the  I-mediated  *C4b fragmentation at  low  *C4b 
density when *C3b is present on the same cells. EAC 14 (5 x  107/ml) bearing 1 x  10  s molecules 
195  ,  of  I-  C4h per cell were incubated with 300 SFU of C2 and then with increasing amounts 
of ~SlI-labeled C3. The resulting EAC1423 bearing either 0, 4  x  10  ~, or 1.1, 2.4, 4.7, or 7.2 
x  10  ~ molecules of *C3h per cell were then incubated at 37°C for 30 rain with I (16 #g/mi) 
and CR1  (800 ng/ml). Release of 1251-C4 radiolabel is shown as a  function of density of lslI- 
*C3b on the cells. The release increased in a dose-dependent fashion with *C3b density. The 
release in the presence of I  (16 #g/ml) alone was not significantly greater than that in the 
presence of DGVB  +÷ 
EAC1423  bearing  an  eightfold  molar  excess  of unlabeled  *C3b  (2.4  ×  104 
molecules  per  cell).  After  decay  of original  C2a  from  the  DGVB++-treated 
EAC142  and  from  the  EAC1423,  the  cells  were  reincubated  with  multiple 
dilutions of C2. The resulting intermediates,  EAC142 and EAC1423 (5  ×  ]07/ 
ml) bearing various amounts of new C2a, were then  incubated at 37°C for 60 
min with I (16 #g/ml) and CR1 (200 ng/ml) and the percentage of release of C4 
radiolabel determined. The results are shown in Fig. 5.  Reincubation with large 
amounts of C2 (2,500 SFU) significantly inhibited the release of C4 label from 
EAC 142. Prior presence of *C3b, however, at a  *C3b/*C4b molar ratio of 8: l, 
reversed the C2-mediated inhibition. 
It is also of interest  to note  that  in  previous studies  (28-30)  relatively  high 
concentrations of the control proteins  I and  C4bp and  1-2 h  of incubation  at 
37°C  have been  required  to release significant  amounts  of C4c from  EAC14. 
After fixation  of optimal  amounts  of *C3b,  however,  we observed significant 
release of C4 label after incubation for only 30 min at 30°C in the presence of 
as little as 2 #g/ml of I and 25 ng/ml of CR l. As expected, under these conditions 
there was minimal  release of C4 fragments in the presence of I alone or I plus 
C4bp. 
Evidence  that *C4b Can Enhance the 1 plus CR 1-mediated Degradation  of *C3b on 
the Ceil Intermediate  EAC1423.  To examine the influence of *C4b on the CR1- 
mediated degradation of neighboring *C3b, we used guinea pig C4 (4 SFU) and 
C2 (300 SFU) and a concentration of 125I-human  C3 predetermined to yield the 
intermediate  EAC14gP2sP3 hu bearing  limited amounts of C4  gp and  C3 hu (1.5  × 
10 ~ molecules/cell). The cells were washed and after decay of C2a and incubation 
with additional C l, different portions of the EAC 14gP3hu cells were reincubated 
with  increasing  amounts  of human  C4.  The  EAC143,  bearing a  constant  and 
limited  amount  of both  ~I-*C3b hu  and  *C4b  gp,  but  increasing  amounts  of 
*C4b  hu, were then incubated with I plus CR1 as above. As can be seen in Fig. 6, 
the release of C3c was enhanced in a dose-dependent fashion by the addition of MEDOF  AND  NUSSENZWEIG  1675 
55 
g 
~  45 
$ 
~  o  3o~ 
o /r~  /~8  /6  1/2 
C2  Dil,ti0n 
FIGURE 5.  Inhibitory effect of C2a on the degradation of *C4b and reversal of the C2a 
effect by *C3b. EAC]42 (5 X  ]07/ml) bearing 3 x  ]0 ~ molecules of ]~sI-*C4b per cell and 
prepared with  100  SFU  of C2  were  incubated  with  either DGVB  +÷  or  with  30  SFU  of 
unlabeled C3. The resulting cells (5 x  107/ml) bearing the same number of =~5I *C4b molecules 
and either 0 or 2.4 x  104 molecules of *C3b were then decayed at 30°C for 60 rain to remove 
residual  C2a,  reincubated  for  5  min  at  30°C  with  multiple  dilutions  of fresh  C2,  and, 
immediately after washing, incubated for 60 rain at 37°C with I (16 ug]ml) and CR1 (200 ng/ 
ml). The percentage of release of C4 radiolabel is shown as a function of the amount of new 
C2 added in  the absence or presence of *C3b on  the cells.  In the absence of *C3b, C2a 
inhibited I  plus CRl-mediated release of C4  radiolabet in a  dose-dependent fashion. The 
presence of 2.4 x  104 molecules of *C3b not only enhanced release but also reversed the C2a 
effect. 
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FICURE 6.  Enhancing effect of *C4b on  *C3b fragmentation by I  plus CRI  at low *C3b 
,  density and comparative activities of human and guinea pig  C4b. EAC1423 were prepared 
with 5 SFU of C4  ~, 300 SFU of C2  gp, and sufficient human l~SI-C3 (20 SFU) to deposit 1.5 x 
l0  s molecules per cell of '25I *C3b. The EAC14~2~3 h" were then decayed by incubation in 
DGVB  ++ for 60 rain at 30°C to remove C2a and reincubated with additional C1  (300 SFU) 
and then increasing amounts of C4  ha or C4  ~. The resulting cells bearing a  small amount of 
*C4b  ~  and a constant amount of ]2sI-*C3b but increasing amounts of *C4b  h" or additional 
*C4b~'were then incubated at 30°C for 30 rain with I (2 #g/ml) and CR1  (300 ng/ml). The 
percentage of release of C3  radiolabel  is  shown as a  function of the amount  of C4  h" or 
additional C4  ~  added to the cells. The release increased with C4 input and release from cells 
bearing human *C4b was greater than that from cells bearing guinea pig *C4b. 1676  CONTROL  OF  C4b-C3b  BY  COMPLEMENT  RECEPTOR  CR1 
*C4b  h".  A  similar  experiment  was performed  in  which  the  same  EAC14gP3h" 
were reincubated with increasing amounts of C4  go. In this case the enhancement 
of release was less marked, most likely because *C4b  gp reacts less efficiently with 
human CR1. 
To obtain further evidence that *C4b enhances the degradation of *C3b, we 
studied the effects of C2  (which interacts  with  *C4b) and  of antibodies to C4. 
EAC 1423 bearing unlabeled *C4b and labeled *C3b were prepared in a conven- 
tional fashion using 300 SFU C4  hu and 5 SFU ~2SI-labeled C3  h". The cells were 
incubated at 30°C for 60 min to decay residual C2a. Then the resulting EAC143 
were incubated with increasing amounts of C2 (100-2,500 SFU), or alternatively, 
with  increasing  amounts  of IgG  from  a  goat  antiserum  to  human  C4.  After 
washing, the cells (5 x  107/ml) were incubated at 30°C for 30 min with I (2 #g/ 
ml)  and  CR1  (100  ng/ml)  and  the  percentage  of release  of  C3  radiolabel 
measured.  As shown  in  Fig.  7,  treatment  of EAC143  with  C2  or exposure to 
anti-C4 antibody inhibited C3c release. Assuming that  10% of the immunoglob- 
ulin in the antiserum  is anti-C4,  we calculate that  1-2 antibody molecules per 
*C4b molecule were sufficient to inhibit *C3b fragmentation. 
The effect of *C4b on I plus CRl-mediated fragmentation of EAC1423i was 
next  examined.  The  rationale  for  these  experiments  was that  *iC3b  has  low 
affinity  for  CR1,  and  therefore  *iC3b  degradation  might  also be greatly  en- 
hanced by neighboring *C4b. EAC 1423 were prepared bearing limited *C4b (4 
SFU of C4) and 1~5I-*C3b (3.5 ×  l0 s molecules/cell) and incubated at 30°C for 
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FIGURE 7.  Inhibitory  effect  of anti-C4b  antibodies  and  of  C2  on  *C3b  fragmentation. 
EAC1423 were prepared with 300 SFU of unlabeled C4 and limited (~5 SFU) of l~nI-C3. The 
resulting cells bearing ~3 ×  10  ~ molecules of unlabeled *C4b and -3 ×  103 molecules of l~I- 
*C3b were decayed at 30°C for 60 min to eliminate residual C2a and then incubated for 5 
min at 30°C with decreasing dilutions of human C2 or goat anti-C4 globulin. Immediately 
after washing, the cells were further incubated at 30°C for 30 rain with I (2 t~g/ml) and CR1 
(100 ng/ml). The percentage of release of C3 radiolabel is shown as a function of the C2 or 
anti-C4 dilution used to pretreat the cells. Under these conditions of limited *C3b, both C2a 
and anti-C4 inhibited the release of C3 radiolabel. The inhibitory effect of anti-C4 was more 
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30 min with I (2 #g/ml) and H (10 #g/ml) to obtain EAC1423i. Hemolytic assays 
revealed >90%  abrogation  of the initial  C3b hemolytic activity on these cells. 
The  cells  were  then  reincubated  with  excess  C1  (300  SFU)  and  increasing 
amounts of C4. The cells were subsequently mixed with I (2 #g/ml) and increasing 
concentrations of CR1  or intact  E he, containing an equivalent amount of CR1. 
Following  incubation  at  30°C  for  30  min,  the  percentage  of release  of C3 
radiolabel was determined (Fig. 8). Release of C3 radiolabel increased in a dose- 
dependent fashion as the amount of human C4 added to the cells was increased, 
whether the release was supported by purified CR1 (Fig. 8A) or by membrane- 
associated CR1 on intact E hu (panel B). Minimal release occurred in the presence 
of I alone, regardless of the C4 concentration used to prepare the cells. 
Kinetics of C4 and C3 Fragmentation.  Kinetic analyses were next performed to 
determine  the temporal  relationship  between *C4b and  *C3b breakdown and 
release. EAC 1423 bearing 3 ×  103 molecules of l zsI-*C4b and 2 ×  104 molecules 
of l~lI-labeled  *C3b (*C3b/*C4b molar ratio  of 7:1),  or EAC142  bearing  the 
same number of lzSI-labeled *C4b molecules, were mixed with I (16 ~g/ml) and 
CR1 (200 ng/ml). After incubation at 37°C for increasing times (2-64 min), the 
reactions were stopped and the percentages of released C4 and C3 labels were 
determined.  As shown in Fig. 9, although the presence of *C3b accelerated the 
release of C4 label from EAC1423 (compared with that from EAC142), almost 
60% of C3 label had already been released before 10% of C4 label was found in 
the supernatant. 
Additional kinetic analyses were performed using cells bearing different *C3b/ 
*C4b ratios.  Release of C3 label preceded that of C4 label in all cases. At very 
high  densities  of bound  *C3b (>10 ~ molecules/cell) and  *C3b/*C4b ratios of 
>50:1,  the initial  rate of release of C4 label from EAC1423  was less than  that 
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FIGURE  8.  Enhancing effect of *C4b on the degradation of bound *iC3b by I plus CR 1 or I 
125  plus E hu. EAC1423  were prepared with limited human C4 (4 SFU) and sufficient  I-C3 to 
yield an  uptake  of 3.5  ×  l0 s  *C3b  molecules per cell.  The  cells (5  x  107]ml)  were  then 
incubated at 30°C for 30 rain with I (2 ~g/ml) and H  (10 ug]ml). Titrations revealed >90% 
loss of C3b hemolytic activity. The EAC 14 lim3i (5 ×  107/ml) were then reincubated at 30 °C 
for 20 min with C1 (300  SFU) and then with  10,  30,  100, or 300 SFU of(human) C4. After 
washing, the cells (5 ×  10~/ml) bearing increasing amounts of *C4b and a constant amount of 
125I-*iC3b were incubated at 30°C for 30 min with I (2 ~g/ml) plus increasing concentrations 
of CR1  or increasing numbers of E h". The percentage of release of C3 radiolabel is shown as 
a function of CR1 or E h" input in A and B, respectively. Addition of *C4b enhanced the release 
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FIGURE 9.  Kinetics  of fragmentation of *C4b and *C3b by I plus CRI. EAC142 (5 x  107/ 
ml) bearing 3 x 103 *C4b molecules  and either 0 or 2 x 104 molecules  of *C3b were incubated 
at 37°C with I (16 ~g/ml) plus CR1  (200 ng/ml) and the reaction stopped after different 
times. The percentage of release of 1z51-C4 label from EAC142 and of 1~5I-C4 and  ]3]I-C3 
labels from EAC1423 are shown as a function of incubation time. The presence of *C3b 
accelerated the release of C4 label. Nevertheless, release of C3 label preceded release of C4 
label. 
from  EAC142.  Nevertheless,  release  of C4  label  after  60  min  at  37°C  from 
EAC1423  in  all  cases studied  exceeded that  from EAC142  (not shown).  Even 
when the *C3b/*C4b ratio was reversed and cells bearing low densities of *C3b 
(1  ×  103 molecules/cell) and high densities of *C4b (8 x  103 molecules/cell) were 
used, release of C3 label still preceded that of C4 label. 
Analysis of the Products of l plus CR 1-mediated Degradation of *C4b on Cells Bearing 
*C4b and *C3b.  Previous studies have shown that the C3b fragments generated 
by I  plus CR1  are the same whether  *C3b is deposited on the substrate by the 
classic (1) or by the alternative pathways (2, 3, 31), indicating that the presence 
of nearby  *C4b  molecules does not alter the pattern  of *C3b breakdown.  To 
determine whether the presence of neighboring *C3b molecules influences the 
pattern of *C4b breakdown, EAC] 4 and EAC1423 were prepared with ]zsI-C4 
and treated with I plus CR I, E h", or C4bp. The supernatants and stroma of each 
reaction mixture were isolated and structural analyses performed by SDS-PAGE 
and radioautography. As shown in Fig.  10, (lanes 1-3, 5, 7) I, CR1, E h", or C4bp 
alone had negligible activity. 
The major fragments released from EAC14 or EAC1423 by I plus CR1, I plus 
E h", or I plus C4bp were identical. They had molecular weights of 140,000 (140 
K) under nonreducing conditions, and after reduction (Fig.  10,  lanes  4,  6,  8), 
they yielded peptides of 75 K and 31  K mol wt, corresponding to/3 and 3' chains, 
and of -25  K  and  17  K  mol wt,  corresponding to o~'3 and a'4 segments of a' 
chain. The amount of released C4c was much smaller in the presence of I  plus 
C4bp (lane 8). 
The SDS-PAGE of the stroma of EAC1423,  isolated after the various treat- 
ments (lanes 9-13) revealed the presence of remaining *C4b a',/3, and 3" chains. MEDOF  AND  NUSSENZWEIG  1679 
FIGURE 10.  SDS-PAGE analysis of *C4b fragments generated by I plus CRI, E hu, or C4bp 
in the presence of *C3b. EAC1423 (5 ×  107/ml), bearing 3 x  l0  s molecules of 1'5I-*C4b and 
2 x  104 molecules of (unlabeled) *C3b, were incubated at 37°C for 60 min with DGVB  +÷, I 
alone (8 ug/ml), CR1  alone (400 ng/ml), E  hu alone (1  x  109/ml),  C4bp alone in equivalent 
blood proportion (30 #g/ml), or with I  plus CR1,  I  plus E  h",  or  I. plus C4bp at  the same 
concentrations.  Samples  of  supernatants and  cell  stroma  in  each  reaction  mixture  were 
subjected to SDS-PAGE under reducing conditions and radioautographs prepared. A  small 
amount of polypeptides with  molecular weights  corresponding to  a',  /3,  and  ~,  chains of 
uncleaved C4b were released into the supernatant by DGVB  +÷, I, CR1, E  hu, or C4bp alone 
(lanes 1, 2, 3, 5, and 7 respectively). Polypeptides with molecular weights corresponding to/3 
and ~, chains, and a'3 and a'4 fragments, were released in small amounts in the presence of I 
alone (lane 2) or I plus C4bp (lane 8) but in much larger amounts in the presence of I plus 
CR1 or I plus E  hu (lanes 4 and 6). The *C4b polypeptides released by I plus CR1 or I plus E  hu 
were identical to those generated in the absence of *C3b (not shown). 
Polypeptides corresponding to the a',/3, and 3' chains of uncleaved *C4b were seen in all 
samples of stroma (lanes 9-13). Additional polypeptides of 75 K tool wt were seen in small 
amounts in samples treated with 1 alone (lane 10) and in greater amounts in samples treated 
with I plus C4bp (lane 13). These quantitative differences are not clearly seen in the above 
radioautography because the a' 75 and 3 chain bands appear fused (the time of exposure was 
increased to show the a' fragments released in the supernatant). In lane 14 we show a repeat 
of the radioautography of lane 13 with less exposure time to permit the distinction between 
the a' 75 and 3 peptides. 
Polypeptides of 45 K mol wt (probably resulting from further cleavage of the 75 K mol wt 
fragments) were prominent only in samples treated with I plus CR1  or I plus E  h" (lanes 11, 
12). Identical peptides were observed in the absence of *C3b (not shown) except that small 
amounts of 45 K mol wt peptides were also seen in samples treated with I plus C4bp. 
EAC 1423  stroma  treated  with  I  and  the different  cofactors  additionally yielded 
peptides  of 45  K  mol wt presumably  representing  covalently bound  a'2  (*C4d) 
fragments,  as  well  as  peptides  of 75  K  mol  wt,  which  appear  fused  with  the/3 
chain band.  In lane  14 we show a  repeat  of the radioautography  of lane  13  with 1680  CONTROL  OF  C4b-C3b  BY  COMPLEMENT  RECEPTOR  CR1 
less  exposure  time,  which  permits  the  distinction  between  the  a'75  and  /3 
peptides. 
A comparison of the patterns seen in samples derived from the stroma of cells 
treated with I plus C4bp with those in samples treated with I plus CR1  or I plus 
E  hu showed that they differed in that the proportion of the 45 K mol wt peptide 
relative to the 75 K tool wt peptide was much smaller in the samples treated with 
C4bp  plus  I  (lane  13).  The high  molecular weight bands  seen  in  lanes  9-13 
probably represent o~' chain fragments covalently bound to macromolecules from 
the cell membrane. 
Discussion 
The mechanisms regulating the function of *C4b have remained incompletely 
understood. Although C4bp is required for cleavage of fluid phase C4b by I, the 
od chain of *C4b can be cleaved successively at two or more sites by I alone and 
C4c subsequently released from the substrate (19,  30).  Relatively high concen- 
trations of I and prolonged incubation are necessary, however, and degradation 
is usually incomplete. One study (29) shows that C4bp can enhance this reaction, 
while another (19) reports that C4bp has no effect. Recently, Fujita and Tamura 
(28) have resolved this controversy by showing that an enhancing action of C4bp 
can be demonstrated only at high *C4b density (>3 x  l0  s molecules/cell). 
Initial  experiments of ours  (1)  indicated that  CR1  also  did  not  appear  to 
substantially alter  I-mediated release of C4c.  These earlier studies were per- 
formed with low concentrations of I and CR1  and a temperature of incubation 
of 30°C;  that is,  under reaction conditions similar to  those which we used to 
study  degradation  of  *C3b.  In  the  present  paper  we  present  the  results  of 
additional studies, performed under different experimental conditions. We show 
here that in the presence of higher concentrations of I, CR1  does promote the 
degradation of *C4b on EAC14 cells provided that the density of *C4b is >3 x 
103 molecules per cell, and that the incubation is carried out at either 37°C or 
alternatively for longer periods of time at 30°C.  Under these conditions, on a 
weight basis,  CRI is -10a-fold more effective than C4bp in promoting fragmen- 
tation of *C4b on EAC 14 (Fig. 2). Since it could be argued that the behavior of 
the detergent-extracted and  purified  CR1  in  an  aqueous environment might 
differ from that of membrane-associated CR 1, these and other experiments (Figs. 
2,  8,  10)  were also performed using intact human erythrocytes as a  source of 
receptor. The results showed that the CR1  activity on E  hu and in purified form 
was comparable. In addition, the experiments revealed that the cofactor activity 
of erythrocytes was almost exclusively mediated by CR1,  since it was strongly 
inhibited by monoclonat antibodies to the receptor (Fig. 2). 
Perhaps of greater significance is the finding that the breakdown of *C4b by 
I plus CR1  was enhanced by the presence of *C3b on the cellular intermediates 
(Fig.  3).  On EAC1423  cells, CR1  supported the *C4b breakdown even at low 
*C4b densities and low concentrations of I and CR 1, under incubation conditions 
comparable to  those required for *C3b  breakdown (1).  It appears,  therefore, 
that in the physiological situation, before *C3b uptake, *C4b is less vulnerable 
to attack by I.  Once optimal  *C3b  uptake has taken place, binding to CR1  is MEDOF AND NUSSENZWEIG  1681 
enhanced and  the  activities  of the  *C4b-  and  *C3b-dependent  enzymes are 
inhibited. 
Despite the marked difference in efficiency between CR1  and C4bp in pro- 
moting I-mediated *C4b fragmentation, similar degradation products were ob- 
tained from EAC14 or EAC1423 cells (Fig. 10). The C4c fragment released into 
the supernatant,  after incubation with  I  and either cofactor, had a  molecular 
weight of 140  K and consisted of polypeptides of 75  K,  31  K, 25 K, and 17 K 
mol wt, corresponding to ~ and 3' chains and od3 and a'4 segments, respectively. 
The bands remaining associated with the cell had molecular weights of about 75 
K  and 45  K,  the latter most likely representing *C4d  (28,  30).  As shown by 
Fujita and Tamura (28), the 75 K band derives from an intermediate product of 
degradation of C4b (iC4b) first described by Nagasawa et al. (32). The results of 
multiple experiments, one of them represented in Fig.  10, showed that the 45 
K/75K ratio was much higher in *C4b samples treated with I plus CR1  than in 
those treated with  I  plus C4bp,  suggesting that the cleavage of *iC4b by I  is 
promoted  by  CR1  more  effectively than  by  C4bp.  These  findings  indicate, 
therefore, that the efficiency of the I-mediated conversion of *C4b into C4c and 
*C4d  is  substantially  greater  in  the  presence  of  CR1  than  of C4bp.  This 
difference in  the  effects between  I  plus  CR1  and  I  plus  C4bp  parallels  the 
differential effects of I plus CR1  and I plus H on *C3b (1, 4). 
In analogy to the above findings showing that *C3b enhances degradation of 
*C4b, studies with cells bearing limited amounts of *C3b demonstrated a parallel 
potentiating effect of *C4b on *C3b degradation. That this effect was indeed 
mediated by *C4b was shown by several observations. For example, binding of 
C2a or anti-C4 antibody to  *C4b  on EAC14231im  inhibited the I  plus CR1- 
mediated  C3c  release  (Fig.  7).  Reduction  of  *C4b  density  on  the  cells  or 
replacement of human *C4b by guinea pig *C4b (which most likely has a lower 
binding affinity for human CR1) had a similar effect (Fig. 6). Uptake of additional 
*C4b  onto  EAC143i  increased  I  plus  CRl-mediated  C3c  release  in  a  dose- 
dependent fashion (Fig. 8). The most plausible mechanism of these effects is that 
*C4b promotes interaction of *C3b or *iC3b with CR1. 
Provided that the kinetics of C3c and C4c release from EAC 1423 treated with 
CR1  plus I (Fig. 9) parallel the kinetics of the underlying proteolysis of the a' 
chains of *C3b and *C4b,  the enzymatic attack on  *C3b proceeds faster than 
that on  *C4b.  The  simplest explanation  for this  observation is  that  CR1  has 
greater affinity for *C3b than for *C4b.  It is also conceivable that the spatial 
arrangement of *C3b and *C4b on the substrate could influence the outcome 
of the  reaction  if multiple  bonds  have  to  be  formed between  CR1  and  the 
substrate-bound ligands before the inactivator I can fully exert its effect. 
The finding that *C4b can enhance *C3b interaction with CR 1, taken together 
with  the  results  above  that  the  converse  is  also  true,  argue  that  clusters  of 
*C4b*3b can serve as a ligand for CR1, which is itself probably multivalent (33, 
34). This notion is consistent with previous observations that *C3b can enhance 
the rosetting of EAC14 with E  hu, and that excess *C4b can enhance rosetting of 
EAC 14231 im (18). A greater ability of *C4b*3b clusters than of *C4b or *C3b 
monomers alone  to  interact  with  CR1  is  also  compatible  with  more  recent 
findings (35) that C3b dimer binds to CR 1 with high affinity, while C3b monomer 1682  CONTROL  OF  C4b-C3b  BY  COMPLEMENT  RECEPTOR  CR1 
does not. The formation of multiple bonds between ligand and CR 1 can likewise 
account for the observation (4)  that the activity of CR1  in  the inactivation of 
classical  pathway C5-convertase can be much greater than that of H, and that 
CR1  activity can  increase progressively with  increasing *C3b  density on  the 
substrate.  This latter result,  in  conjunction with longstanding observations by 
many investigators that rosetting between EAC14 and E  hu occurs only at very 
high *C4b densities, and the multiple data showing cooperation between *C4b 
and  *C3b  in  the present  study,  suggests  that  effective interaction  with  CR1 
requires a multivalent ligand which can consist of clusters of *C4b, *C3b, *iC3b, 
*iC4b, or of these fragments, in various combinations. 
In summary, the present results strongly suggest that *C4b is more effectively 
inactivated when  *C3b  is  fixed, and that  the inactivation of *C4b*3b  by I  is 
greatly enhanced by CR1,  but not by C4bp.  The greater ability of CR1  than 
C4bp to serve as a cofactor of I in this reaction can be explained by the lack of 
high binding affinity of C4bp  for *C3b  (30),  but steric considerations arising 
from the muitimeric nature of the interaction between substrate and cofactor 
may also be important. The findings of this paper also have implications in the 
pathophysiology of complement deficiency diseases. For example, they predict 
that in C2-deficient individuals, *C4b should persist and thereby accumulate to 
a greater extent on substrates, since in these individuals *C3b cannot be deposited 
by the classical  pathway and *C4b inactivation therefore should be less efficient. 
On  the other hand,  when CR1  levels on  erythrocytes are diminished, as,  for 
example, can occur in patients with systemic lupus erythematosus (11-15), *C4b 
and *C4b*3b clusters will be less subject to I-mediated control and complement 
consumption by the classical  pathway will increase. 
Summary 
The  complement  fragments  C3b  and  C4b  are  the  main  ligands  for  the 
membrane  receptor  CR1.  We  showed  elsewhere  that  CR1  functions  as  an 
essential cofactor for the factor I-mediated enzymatic breakdown of membrane- 
bound C3b (*C3b) into C3c and *C3dg. One of the main findings of the present 
paper is that CR1 also promotes the degradation of bound C4b (*C4b) into C4c 
and  *C4d.  On a  weight basis,  the cofactor activity of CRI  in  the cleavage of 
*C4b present on the cell intermediate EAC14 is  103-fold  greater than that of 
the serum cofactor C4-binding protein (C4bp). 
An additional finding is  that the effect of CR1  on either  *C3b  or  *C4b  is 
modulated by  the presence  of the  other  ligand  in  its  vicinity;  that  is,  *C4b 
degradation by CR1  plus I is enhanced by neighboring *C3b and vice versa. For 
example,  upon  uptake  of optimal  amounts  of  *C3b  onto  EAC142  and  the 
assembly of the C3-convertase EAC1423, the activity of CR1  in generating C4c 
is enhanced 5-10 times further. Conversely, when the number of *C3b molecules 
on EAC1423 is relatively small (or when EAC1423 has been converted by I plus 
H  into EAC 1423i), the presence of neighboring *C4b enhances the conversion 
of *C3b (or *iC3b) into C3c plus *C3dg. 
The enhancing effect of *C3b on the cleavage of *C4b by I is observed only 
if the cofactor of this reaction is CR1. Indeed, the activity of I or I plus C4bp on 
*C4b is significantly inhibited when *C3b is fixed and the main product of the MEDOF AND  NUSSENZWEIG  1683 
reaction is  *iC4b.  Taken  together,  these  findings  suggest  that  degradation  of 
*C4b will be more effective when enough C3b molecules are fixed nearby, thus 
facilitating the interaction of *C4b*3b clusters with CRl-bearing cells, and that 
under  physiological  conditions,  *C4b  activity can  be  efficiently controlled by 
CR1. 
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